These epidemiologic patterns highlight the limitations of focusing on genetics alone. Although the Human Genome Project greatly expanded our understanding of hereditary contributions to disease ...

Study demonstrates PLT012 reprograms tumor immunity by targeting metabolic suppression in hepatocellular carcinoma (HCC) and liver metastases Findings establish proof-of-concept for CD36 as a ...

Details are provided in a new Cell paper titled, “CD36-mediated endocytosis of proteolysis-targeting chimeras.” PROTACs are small molecules that use the ubiquitin-proteasome system to remove ...

The new method works by taking advantage of a protein called CD36 that helps pull substances into cells. By designing drugs to use this CD36 pathway, researchers delivered 7.7 to 22.3 times more ...

The new method works by taking advantage of a protein called CD36 that helps pull substances into cells. By designing drugs to use this CD36 pathway, researchers delivered 7.7 to 22.3 times more ...

Opening this channel on acidic vesicles releases protons, increasing the pH inside the vesicles and activating TFEB. Dr. Yan and his colleagues hypothesize that because lysosomes normally degrade ...

How these EC immune cells can contribute to the brain immunity when implicated by CD36 (an innate immune receptor) is widely unknown. To understand this question, we wanted to investigate how CD36 ...

TFEB is a master regulator of autophagy, lysosome biogenesis, mitochondrial metabolism, and immunity that works primarily through transcription controlled by cytosol-to-nuclear translocation. Emerging ...

Renal cell carcinoma (RCC) is one of the 10 most commonly diagnosed solid tumors. Most RCCs are histologically defined as clear cell, comprising approximately 75% of diagnoses. However, the remaining ...

SNX10 deficiency inhibits CD36 internalization and foam cell formation by suppressing the Lyn-AKT (protein kinase B) pathway, resulting in increased nuclear translocation of TFEB (transcription factor ...

The grant, which will support the development of Coave’s CTx-TFEB program through to preclinical proof-of-concept, has been made through the Association’s Lawrence and Isabel Barnett Drug ...